{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:41:23Z","timestamp":1763037683461},"reference-count":69,"publisher":"Medical Journals Sweden AB","issue":"12","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["www.medicaljournals.se"],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Numerous cases of chilblains have been observed in the course if the COVID-19 pandemic. The aims of this study were to provide comprehensive follow-up data for patients reporting chilblains, and to determine the risk factors for incomplete recovery. Patients referred to 5 hospitals in France between March and May 2020 for chilblains were surveyed on December 2020. A teleconsultation was offered. Among 82 patients reporting chilblains, 27 (33%) reported complete recovery, 33 (40%) had recurrences of chilblains after their hands and feet had returned to normal, and 22 (27%) developed persistent acral manifestations, mostly acrocyanosis, with or without further recurrences of chilblains. Most recurrences of chilblains occurred during the following autumn and winter. A past history of chilblains was not associated with recurrences or persistent acral manifestations. Women had a significantly higher risk of developing recurrences or persistent acral manifestations (odds ratio 1.30; 95% confidence interval 1.06\u20131.59). In conclusion, two-thirds of patients reporting chilblains at the start of the COVID-19 pandemic experienced persistent or recurrent acral manifestations after a 10-month follow-up.<\/jats:p>","DOI":"10.2340\/00015555-3930","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T14:25:59Z","timestamp":1631543159000},"page":"adv00614","update-policy":"http:\/\/dx.doi.org\/10.2340\/adv_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-term Outcome of Chilblains Associated with SARS-CoV-2"],"prefix":"10.2340","volume":"101","author":[{"given":"Florence","family":"Poizeau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Barbarot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"Le Corre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Brenaut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahtab","family":"Samimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Aubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Toubel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Dupuy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"11576","doi-asserted-by":"crossref","unstructured":"Recalcati S, Barbagallo T, Frasin LA, Prestinari F, Cogliardi A, Provero MC, et al. Acral cutaneous lesions in the time of COVID-19. J Eur Acad Dermatol Venereol 2020; 34: e346-347.","DOI":"10.1111\/jdv.16533"},{"key":"11577","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.16533","DOI":"10.1111\/jdv.16533"},{"key":"11578","doi-asserted-by":"crossref","unstructured":"Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Takeshita J, et al. Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries. J Am Acad Dermatol 2020; 83: 486-492.","DOI":"10.1016\/j.jaad.2020.05.109"},{"key":"11579","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2020.05.109","DOI":"10.1016\/j.jaad.2020.05.109"},{"key":"11580","doi-asserted-by":"crossref","unstructured":"Le Cleach L, Dousset L, Assier H, Fourati S, Barbarot S, Boulard C, et al. Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing. Br J Dermatol 2020; 183: 866-874.","DOI":"10.1111\/bjd.19377"},{"key":"11581","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.19377","DOI":"10.1111\/bjd.19377"},{"key":"11582","doi-asserted-by":"crossref","unstructured":"Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A, Moreno-Arrones OM, Saceda-Corralo D, Arana-Raja A, et al. Characterization of acute acral skin lesions in nonhospitalized patients: a case series of 132 patients during the COVID-19 outbreak. J Am Acad Dermatol 2020; 83: e61-e63.","DOI":"10.1016\/j.jaad.2020.04.093"},{"key":"11583","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2020.04.093","DOI":"10.1016\/j.jaad.2020.04.093"},{"key":"11584","doi-asserted-by":"crossref","unstructured":"de Masson A, Bouaziz J-D, Sulimovic L, Cassius C, Jachiet M, Ionescu M-A, et al. Chilblains is a common cutaneous finding during the COVID-19 pandemic: a retrospective nationwide study from France. J Am Acad Dermatol 2020; 83: 667-670.","DOI":"10.1016\/j.jaad.2020.04.161"},{"key":"11585","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2020.04.161","DOI":"10.1016\/j.jaad.2020.04.161"},{"key":"11586","doi-asserted-by":"crossref","unstructured":"Galv\u00e1n Casas C, Catal\u00e0 A, Carretero Hern\u00e1ndez G, Rodr\u00edguez-Jim\u00e9nez P, Fern\u00e1ndez-Nieto D, Rodr\u00edguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020; 183: 71-77.","DOI":"10.1111\/bjd.19163"},{"key":"11587","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.19163","DOI":"10.1111\/bjd.19163"},{"key":"11588","doi-asserted-by":"crossref","unstructured":"Piccolo V, Neri I, Filippeschi C, Oranges T, Argenziano G, Battarra VC, et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. J Eur Acad Dermatol Venereol 2020; 34: e291-293.","DOI":"10.1111\/jdv.16526"},{"key":"11589","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.16526","DOI":"10.1111\/jdv.16526"},{"key":"11590","doi-asserted-by":"crossref","unstructured":"Hubiche T, Cardot-Leccia N, Le Duff F, Seitz-Polski B, Giordana P, Chiaverini C, et al. Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic. JAMA Dermatol 2021; 157: 202-206.","DOI":"10.1001\/jamadermatol.2020.4324"},{"key":"11591","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.4324","DOI":"10.1001\/jamadermatol.2020.4324"},{"key":"11592","doi-asserted-by":"crossref","unstructured":"Herman A, Peeters C, Verroken A, Tromme I, Tennstedt D, Marot L, et al. Evaluation of chilblains as a manifestation of the COVID-19 pandemic. JAMA Dermatol 2020; 156: 998-1003.","DOI":"10.1001\/jamadermatol.2020.2368"},{"key":"11593","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.2368","DOI":"10.1001\/jamadermatol.2020.2368"},{"key":"11594","doi-asserted-by":"crossref","unstructured":"Bessis D. Impaired type I interferon response in SARS-CoV-2 infection: looking through the cutaneous window. Br J Dermatol 2021; 184: 11-12.","DOI":"10.1111\/bjd.19596"},{"key":"11595","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.19596","DOI":"10.1111\/bjd.19596"},{"key":"11596","doi-asserted-by":"crossref","unstructured":"Magro CM, Mulvey JJ, Laurence J, Sanders S, Crowson AN, Grossman M, et al. The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series. Br J Dermatol 2021; 184: 141-150.","DOI":"10.1111\/bjd.19415"},{"key":"11597","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.19415","DOI":"10.1111\/bjd.19415"},{"key":"11598","doi-asserted-by":"crossref","unstructured":"Lipsker D. Paraviral eruptions in the era of COVID-19: do some skin manifestations point to a natural resistance to SARS-CoV-2? Clin Dermatol 2020; 38: 757-761.","DOI":"10.1016\/j.clindermatol.2020.06.005"},{"key":"11599","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clindermatol.2020.06.005","DOI":"10.1016\/j.clindermatol.2020.06.005"},{"key":"11600","doi-asserted-by":"crossref","unstructured":"Damsky W, Peterson D, King B. When interferon tiptoes through COVID-19: pernio-like lesions and their prognostic implications during SARS-CoV-2 infection. J Am Acad Dermatol 2020; 83: e269-e270.","DOI":"10.1016\/j.jaad.2020.06.052"},{"key":"11601","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2020.06.052","DOI":"10.1016\/j.jaad.2020.06.052"},{"key":"11602","doi-asserted-by":"crossref","unstructured":"Maanaoui S, Salez F, Carpentier O. Recurrence of chilblains during a second contact with SARS-CoV-2: a case report. Br J Dermatol 2021; 185: 227-228.","DOI":"10.1111\/bjd.20070"},{"key":"11603","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.20070","DOI":"10.1111\/bjd.20070"},{"key":"11604","doi-asserted-by":"crossref","unstructured":"McMahon DE, Gallman AE, Hruza GJ, Rosenbach M, Lipoff JB, Desai SR, et al. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. Lancet Infect Dis 2021; 21: 313-314.","DOI":"10.1016\/S1473-3099(20)30986-5"},{"key":"11605","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1473-3099(20)30986-5","DOI":"10.1016\/S1473-3099(20)30986-5"},{"key":"11606","doi-asserted-by":"crossref","unstructured":"Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Desai SR, Fassett M, et al. Cold and COVID: recurrent pernio during the COVID-19 pandemic. Br J Dermatol 2021; 185: 214-216.","DOI":"10.1111\/bjd.19894"},{"key":"11607","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.19894","DOI":"10.1111\/bjd.19894"},{"key":"11608","doi-asserted-by":"crossref","unstructured":"Signa S, Sementa AR, Coccia MC, Pastorino C, Viglizzo G, Viola S, et al. Recurrence of previous chilblain lesions during the second wave of COVID-19: can we still doubt the correlation with SARS-CoV-2? J Eur Acad Dermatol Venereol 2021; 35: e475-e477.","DOI":"10.1111\/jdv.17283"},{"key":"11609","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.17283","DOI":"10.1111\/jdv.17283"},{"key":"11610","doi-asserted-by":"crossref","unstructured":"Recalcati S, Barbagallo T, Tonolo S, Milani M, Fantini F. Relapse of chilblain-like lesions during the second wave of coronavirus disease 19. J Eur Acad Dermatol Venereol 2021; 35: e315-e316.","DOI":"10.1111\/jdv.17168"},{"key":"11611","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.17168","DOI":"10.1111\/jdv.17168"},{"key":"11612","doi-asserted-by":"crossref","unstructured":"Moghadam P, Frumholtz L, Jaume L, De Masson A, Jachiet M, Begon E, et al. Frequency of relapse and persistent cutaneous symptoms after a first episode of chilblain-like lesion during the COVID-19 pandemic. J Eur Acad Dermatol Venereol 2021; 35: e566-e568.","DOI":"10.1111\/jdv.17393"},{"key":"11613","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.17393","DOI":"10.1111\/jdv.17393"},{"key":"11614","doi-asserted-by":"crossref","unstructured":"Hubiche T, Le Duff F, Fontas E, Rapp J, Chiaverini C, Passeron T. Relapse of chilblain-like lesions during the second wave of the COVID-19 pandemic: a cohort follow-up. Br J Dermatol 2021; 185: 858-859.","DOI":"10.1111\/bjd.20584"},{"key":"11615","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.20584","DOI":"10.1111\/bjd.20584"},{"key":"11616","doi-asserted-by":"crossref","unstructured":"Poizeau F, Oger E, Barbarot S, Le Corre Y, Samimi M, Brenaut E, et al. Chilblains during lockdown are associated with household exposure to SARS-CoV-2. A multicentre case-control study. Clin Microbiol Infect 2021 Oct 4 [Online ahead of print].","DOI":"10.1016\/j.cmi.2021.09.032"},{"key":"11617","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.cmi.2021.09.032","DOI":"10.1016\/j.cmi.2021.09.032"},{"key":"11618","unstructured":"Creamer D. Reactions to cold. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's textbook of dermatology. Eighth edn. Wiley-Blackwell, Chichester, West Sussex, UK, 2010: p. 28.65-67."},{"key":"11619","doi-asserted-by":"crossref","unstructured":"McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol 2021; 85: 46-55.","DOI":"10.1016\/j.jaad.2021.03.092"},{"key":"11620","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2021.03.092","DOI":"10.1016\/j.jaad.2021.03.092"},{"key":"11621","doi-asserted-by":"crossref","unstructured":"Kanitakis J, Lesort C, Danset M, Jullien D. Chilblain-like acral lesions during the COVID-19 pandemic (\"COVID toes\"): histologic, immunofluorescence, and immunohistochemical study of 17 cases. J Am Acad Dermatol 2020; 83: 870-875.","DOI":"10.1016\/j.jaad.2020.05.145"},{"key":"11622","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2020.05.145","DOI":"10.1016\/j.jaad.2020.05.145"},{"key":"11623","doi-asserted-by":"crossref","unstructured":"Aschoff R, Zimmermann N, Beissert S, G\u00fcnther C. Type I interferon signature in chilblain-like lesions associated with the COVID-19 pandemic. Dermatopathol 2020; 7: 57-63.","DOI":"10.3390\/dermatopathology7030010"},{"key":"11624","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/dermatopathology7030010","DOI":"10.3390\/dermatopathology7030010"},{"key":"11625","doi-asserted-by":"crossref","unstructured":"Ortega-Quijano D, Fernandez-Nieto D, Jimenez-Cauhe J, Cortes-Cuevas JL, Marcos-Mencia D, Rodriguez-Dominguez M, et al. Association between COVID-19 and chilblains: a case-control study. J Eur Acad Dermatol Venereol 2021; 35: e359-e361.","DOI":"10.1111\/jdv.17195"},{"key":"11626","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.17195","DOI":"10.1111\/jdv.17195"},{"key":"11627","doi-asserted-by":"crossref","unstructured":"Jabalameli N, Rajabi F, Firooz A, Rezaei N. The overlap between genetic susceptibility to COVID-19 and skin diseases. Immunol Invest 2021 Jan 26 [Epub ahead of print].","DOI":"10.1080\/08820139.2021.1876086"},{"key":"11628","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/08820139.2021.1876086","DOI":"10.1080\/08820139.2021.1876086"},{"key":"11629","doi-asserted-by":"crossref","unstructured":"Volpi S, Picco P, Caorsi R, Candotti F, Gattorno M. Type I interferonopathies in pediatric rheumatology. Pediatr Rheumatol Online J 2016; 14: 35.","DOI":"10.1186\/s12969-016-0094-4"},{"key":"11630","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12969-016-0094-4","DOI":"10.1186\/s12969-016-0094-4"},{"key":"11631","doi-asserted-by":"crossref","unstructured":"Campo-Voegeli A, Estrach T, Marti RM, Corominas N, Tuset M, Mascar\u00f3 JM. Acrocyanosis induced by interferon alpha(2a). Dermatology 1998; 196: 361-363.","DOI":"10.1159\/000017917"},{"key":"11632","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000017917","DOI":"10.1159\/000017917"},{"key":"11633","doi-asserted-by":"crossref","unstructured":"Kruit WH, Eggermont AM, Stoter G. Interferon-alpha induced Raynaud's syndrome. Ann Oncol 2000; 11: 1501-1502.","DOI":"10.1023\/A:1026586629166"},{"key":"11634","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1023\/A:1026586629166","DOI":"10.1023\/A:1026586629166"},{"key":"11635","doi-asserted-by":"crossref","unstructured":"Carf\u00ec A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324: 603-605.","DOI":"10.1001\/jama.2020.12603"},{"key":"11636","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jama.2020.12603","DOI":"10.1001\/jama.2020.12603"},{"key":"11637","doi-asserted-by":"crossref","unstructured":"Petersen MS, Kristiansen MF, Hanusson KD, Danielsen ME, \u00e1 Steig B, Gaini S, et al. Long COVID in the Faroe Islands: a longitudinal study among nonhospitalized patients. Clin Infect Dis 2021; 73: e4058-e4063.","DOI":"10.1093\/cid\/ciaa1792"},{"key":"11638","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/cid\/ciaa1792","DOI":"10.1093\/cid\/ciaa1792"},{"key":"11639","doi-asserted-by":"crossref","unstructured":"Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open 2021; 4: e210830.","DOI":"10.1001\/jamanetworkopen.2021.0830"},{"key":"11640","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0830","DOI":"10.1001\/jamanetworkopen.2021.0830"},{"key":"11641","doi-asserted-by":"crossref","unstructured":"Salmon-Ceron D, Slama D, De Broucker T, Karmochkine M, Pavie J, Sorbets E, et al. Clinical, virological and imaging profile in patients with prolonged forms of COVID-19: a cross-sectional study. J Infect 2021; 82: e1-4.","DOI":"10.1016\/j.jinf.2020.12.002"},{"key":"11642","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jinf.2020.12.002","DOI":"10.1016\/j.jinf.2020.12.002"},{"key":"11643","doi-asserted-by":"crossref","unstructured":"Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19. JAMA Netw Open 2021; 4: e2111417.","DOI":"10.1001\/jamanetworkopen.2021.11417"},{"key":"11644","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.11417","DOI":"10.1001\/jamanetworkopen.2021.11417"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/1007\/1353","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/1007\/1354","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/1007\/1353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T09:20:23Z","timestamp":1675761623000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/1007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":69,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.2340\/00015555-3930","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,13]]}}}